ABBV
AbbVie Inc.
Price Chart
Latest Quote
$227.23
+2.29 (+1.02%)
Current Price
| Previous Close | $224.94 |
| Open | $227.37 |
| Day High | $230.47 |
| Day Low | $226.00 |
| Volume | 4,818,022 |
Stock Information
| Quarterly Dividend / Yield | $6.92 / 3.08% |
| Shares Outstanding | 1.77B |
| Quarterly Dividend Yield | 3.08% |
| Quarterly Dividend | $6.92 |
| Total Debt | $72.91B |
| Cash Equivalents | $9.39B |
| Revenue | $62.82B |
| Net Income | $3.60B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market Cap | $401.47B |
| P/E Ratio | 110.84 |
| EPS (TTM) | $2.05 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $460.99B |
| Sales | $62.82B |
| Income | $3.60B |
| Book/sh | $-3.77 |
| Cash/sh | $5.32 |
| Employees | 57K |
Financial Ratios
| Quick Ratio | 0.52 |
| Current Ratio | 0.80 |
| EPS Growth TTM | -46.00% |
Returns & Margins
| ROA | 10.03% |
| Gross Margin | 72.03% |
| Operating Margin | 32.16% |
| Profit Margin | 5.79% |
Ownership
| Insider Ownership | 0.11% |
| Institutional Ownership | 76.91% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 13.99 |
| PEG | 0.60 |
| P/S | 6.39 |
| P/B | -60.32 |
Analyst Data
| Recommendation | buy |
| Target Price | $252.90 |
Technical Indicators
| SMA20 | $213.50 |
| SMA50 | $209.16 |
| SMA200 | $217.24 |
| RSI | 72.00 |
| ATR | 5.4850 |
| Shares Float | 1.76B |
| Short Float | 1.42% |
| Short Ratio | 3.39 |
| Volatility | 0.31 |
| Rel Volume | 0.88 |
Performance History
| Week | +4.37% |
| Month | +10.83% |
| Quarter | -0.43% |
| 6 Months | +0.31% |
| YTD | +0.72% |
| Year | +25.24% |
| 3 Years | +83.41% |
| 5 Years | +142.13% |
| 10 Years | +446.18% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $227.23 | 4,818,022 |
| 2026-06-04 | $224.94 | 6,782,000 |
| 2026-06-03 | $217.13 | 5,667,500 |
| 2026-06-02 | $215.40 | 5,861,800 |
| 2026-06-01 | $212.93 | 4,858,400 |
| 2026-05-29 | $217.72 | 7,618,500 |
| 2026-05-28 | $218.63 | 5,189,300 |
| 2026-05-27 | $215.40 | 4,640,100 |
| 2026-05-26 | $213.12 | 4,706,700 |
| 2026-05-22 | $215.70 | 5,406,100 |
| 2026-05-21 | $214.50 | 3,813,800 |
| 2026-05-20 | $212.30 | 5,129,000 |
| 2026-05-19 | $213.76 | 7,220,300 |
| 2026-05-18 | $209.41 | 5,069,000 |
| 2026-05-15 | $210.39 | 5,385,000 |
| 2026-05-14 | $210.77 | 5,006,500 |
| 2026-05-13 | $208.50 | 5,705,700 |
| 2026-05-12 | $207.86 | 7,044,100 |
| 2026-05-11 | $202.78 | 4,931,700 |
| 2026-05-08 | $201.55 | 4,915,400 |
| 2026-05-07 | $202.71 | 6,681,100 |
| 2026-05-06 | $205.03 | 7,290,000 |
About AbbVie Inc.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
đ° Latest News
3 Stocks That Could Be Trading At A Discount Of Up To 34.5%
Simply Wall St. âĸ 2026-06-05T17:38:14Z
June 2026's Top Stocks Estimated Below Intrinsic Value
Simply Wall St. âĸ 2026-06-05T11:38:16Z
75% Upside For LLY Stock?
Trefis âĸ 2026-06-04T20:23:28Z
3 Stocks Estimated To Be Trading 16.4% To 42% Below Intrinsic Value
Simply Wall St. âĸ 2026-06-04T17:38:22Z
Does Decnupaz Approval Validate ABBV's ADC Strategy in Oncology?
Zacks âĸ 2026-06-04T14:01:00Z
BioLife Solutions Leads 3 Stocks Estimated To Be Trading Below Fair Value
Simply Wall St. âĸ 2026-06-04T11:38:14Z
The Best Stocks to Invest $500 in Right Now
Motley Fool âĸ 2026-06-04T07:05:00Z
Extreme Networks And 2 Other Stocks That Could Be Trading Below Their Estimated Value
Simply Wall St. âĸ 2026-06-03T17:38:02Z
AbbVie Delivers 400% Returns Beating The S&P 500 by 139%
24/7 Wall St. âĸ 2026-06-03T16:06:00Z
AbbVie Gets EU Nod for Aquipta as Acute Treatment for Migraine
Zacks âĸ 2026-06-03T14:03:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $18,204,000,000 | $16,904,000,000 | $20,415,000,000 | $17,414,000,000 |
| Cost Of Revenue | $18,204,000,000 | $16,904,000,000 | $20,415,000,000 | $17,414,000,000 |
| Total Revenue | $61,160,000,000 | $56,334,000,000 | $54,318,000,000 | $58,054,000,000 |
| Operating Revenue | $61,160,000,000 | $56,334,000,000 | $54,318,000,000 | $58,054,000,000 |
| Expenses | ||||
| Interest Expense | $2,893,000,000 | $2,808,000,000 | $2,224,000,000 | $2,230,000,000 |
| Total Expenses | $41,069,000,000 | $44,440,000,000 | $40,783,000,000 | $39,240,000,000 |
| Other Income Expense | $-10,867,000,000 | $-6,018,000,000 | $-5,601,000,000 | $-3,293,000,000 |
| Other Non Operating Income Expenses | $-5,793,000,000 | $-3,240,000,000 | $-4,677,000,000 | $-2,448,000,000 |
| Net Non Operating Interest Income Expense | $-2,627,000,000 | $-2,160,000,000 | $-1,684,000,000 | $-2,044,000,000 |
| Interest Expense Non Operating | $2,893,000,000 | $2,808,000,000 | $2,224,000,000 | $2,230,000,000 |
| Operating Expense | $22,865,000,000 | $27,536,000,000 | $20,368,000,000 | $21,826,000,000 |
| Other Operating Expenses | $-241,000,000 | $-7,000,000 | $-179,000,000 | $56,000,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $4,226,000,000 | $4,278,000,000 | $4,863,000,000 | $11,836,000,000 |
| Net Interest Income | $-2,627,000,000 | $-2,160,000,000 | $-1,684,000,000 | $-2,044,000,000 |
| Interest Income | $266,000,000 | $648,000,000 | $540,000,000 | $186,000,000 |
| Normalized Income | $7,481,758,981 | $6,472,620,000 | $5,583,720,000 | $12,578,755,000 |
| Net Income From Continuing And Discontinued Operation | $4,226,000,000 | $4,278,000,000 | $4,863,000,000 | $11,836,000,000 |
| Total Operating Income As Reported | $15,075,000,000 | $9,137,000,000 | $12,757,000,000 | $18,117,000,000 |
| Net Income Common Stockholders | $4,186,000,000 | $4,238,000,000 | $4,820,000,000 | $11,782,000,000 |
| Net Income | $4,226,000,000 | $4,278,000,000 | $4,863,000,000 | $11,836,000,000 |
| Net Income Including Noncontrolling Interests | $4,233,000,000 | $4,286,000,000 | $4,873,000,000 | $11,845,000,000 |
| Net Income Continuous Operations | $4,233,000,000 | $4,286,000,000 | $4,873,000,000 | $11,845,000,000 |
| Pretax Income | $6,597,000,000 | $3,716,000,000 | $6,250,000,000 | $13,477,000,000 |
| Special Income Charges | $-5,016,000,000 | $-2,757,000,000 | $-778,000,000 | $-697,000,000 |
| Interest Income Non Operating | $266,000,000 | $648,000,000 | $540,000,000 | $186,000,000 |
| Operating Income | $20,091,000,000 | $11,894,000,000 | $13,535,000,000 | $18,814,000,000 |
| Gross Profit | $42,956,000,000 | $39,430,000,000 | $33,903,000,000 | $40,640,000,000 |
| Per Share | ||||
| Diluted EPS | $2.37 | $2.39 | $2.72 | $6.63 |
| Basic EPS | $2.37 | $2.42 | $2.75 | $6.69 |
| Other | ||||
| Tax Effect Of Unusual Items | $-1,818,241,019 | $-583,380,000 | $-203,280,000 | $-102,245,000 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $22,703,000,000 | $17,688,000,000 | $18,096,000,000 | $25,019,000,000 |
| Total Unusual Items | $-5,074,000,000 | $-2,778,000,000 | $-924,000,000 | $-845,000,000 |
| Total Unusual Items Excluding Goodwill | $-5,074,000,000 | $-2,778,000,000 | $-924,000,000 | $-845,000,000 |
| Reconciled Depreciation | $8,139,000,000 | $8,386,000,000 | $8,698,000,000 | $8,467,000,000 |
| EBITDA (Bullshit earnings) | $17,629,000,000 | $14,910,000,000 | $17,172,000,000 | $24,174,000,000 |
| EBIT | $9,490,000,000 | $6,524,000,000 | $8,474,000,000 | $15,707,000,000 |
| Diluted Average Shares | $1,773,000,000 | $1,773,000,000 | $1,773,000,000 | $1,778,000,000 |
| Basic Average Shares | $1,769,000,000 | $1,765,256,986 | $1,765,940,733 | $1,769,181,294 |
| Diluted NI Availto Com Stockholders | $4,186,000,000 | $4,238,000,000 | $4,820,000,000 | $11,782,000,000 |
| Otherunder Preferred Stock Dividend | $40,000,000 | $40,000,000 | $43,000,000 | $54,000,000 |
| Minority Interests | $-7,000,000 | $-8,000,000 | $-10,000,000 | $-9,000,000 |
| Tax Provision | $2,364,000,000 | $-570,000,000 | $1,377,000,000 | $1,632,000,000 |
| Other Special Charges | $5,016,000,000 | $2,757,000,000 | $778,000,000 | $697,000,000 |
| Gain On Sale Of Security | $-58,000,000 | $-21,000,000 | $-146,000,000 | $-148,000,000 |
| Research And Development | $9,096,000,000 | $12,791,000,000 | $7,675,000,000 | $6,510,000,000 |
| Selling General And Administration | $14,010,000,000 | $14,752,000,000 | $12,872,000,000 | $15,260,000,000 |
Fetched: 2026-05-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-91,551,000,000 | $-91,699,000,000 | $-77,543,000,000 | $-82,341,000,000 |
| Total Assets | $133,960,000,000 | $135,161,000,000 | $134,711,000,000 | $138,805,000,000 |
| Total Non Current Assets | $104,898,000,000 | $109,579,000,000 | $101,709,000,000 | $110,342,000,000 |
| Other Non Current Assets | $10,721,000,000 | $9,142,000,000 | $8,513,000,000 | $5,571,000,000 |
| Goodwill And Other Intangible Assets | $88,281,000,000 | $95,024,000,000 | $87,903,000,000 | $99,595,000,000 |
| Other Intangible Assets | $52,641,000,000 | $60,068,000,000 | $55,610,000,000 | $67,439,000,000 |
| Current Assets | $29,062,000,000 | $25,582,000,000 | $33,002,000,000 | $28,463,000,000 |
| Other Current Assets | $6,265,000,000 | $4,927,000,000 | $4,932,000,000 | $4,401,000,000 |
| Inventory | $4,951,000,000 | $4,181,000,000 | $4,099,000,000 | $3,579,000,000 |
| Receivables | $12,589,000,000 | $10,919,000,000 | $11,155,000,000 | $11,254,000,000 |
| Accounts Receivable | $12,589,000,000 | $10,919,000,000 | $11,155,000,000 | $11,254,000,000 |
| Cash Cash Equivalents And Short Term Investments | $5,257,000,000 | $5,555,000,000 | $12,816,000,000 | $9,229,000,000 |
| Cash And Cash Equivalents | $5,229,000,000 | $5,524,000,000 | $12,814,000,000 | $9,201,000,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $62,267,000,000 | $61,620,000,000 | $46,571,000,000 | $54,070,000,000 |
| Total Debt | $67,496,000,000 | $67,144,000,000 | $59,385,000,000 | $63,271,000,000 |
| Long Term Debt And Capital Lease Obligation | $58,941,000,000 | $60,340,000,000 | $52,194,000,000 | $59,135,000,000 |
| Long Term Debt | $58,941,000,000 | $60,340,000,000 | $52,194,000,000 | $59,135,000,000 |
| Current Debt And Capital Lease Obligation | $8,555,000,000 | $6,804,000,000 | $7,191,000,000 | $4,136,000,000 |
| Current Debt | $8,555,000,000 | $6,804,000,000 | $7,191,000,000 | $4,136,000,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $137,188,000,000 | $131,797,000,000 | $124,314,000,000 | $121,518,000,000 |
| Total Non Current Liabilities Net Minority Interest | $93,899,000,000 | $93,048,000,000 | $86,473,000,000 | $91,980,000,000 |
| Other Non Current Liabilities | $30,795,000,000 | $27,634,000,000 | $28,607,000,000 | $26,032,000,000 |
| Tradeand Other Payables Non Current | $364,000,000 | $1,261,000,000 | $2,182,000,000 | $2,985,000,000 |
| Non Current Deferred Liabilities | $2,389,000,000 | $2,579,000,000 | $1,952,000,000 | $2,190,000,000 |
| Non Current Deferred Taxes Liabilities | $2,389,000,000 | $2,579,000,000 | $1,952,000,000 | $2,190,000,000 |
| Current Liabilities | $43,289,000,000 | $38,749,000,000 | $37,841,000,000 | $29,538,000,000 |
| Payables And Accrued Expenses | $34,734,000,000 | $31,945,000,000 | $30,650,000,000 | $25,402,000,000 |
| Payables | $6,691,000,000 | $5,881,000,000 | $6,471,000,000 | $5,614,000,000 |
| Dividends Payable | $3,099,000,000 | $2,936,000,000 | $2,783,000,000 | $2,680,000,000 |
| Accounts Payable | $3,592,000,000 | $2,945,000,000 | $3,688,000,000 | $2,934,000,000 |
| Current Deferred Liabilities | - | $14,304,000,000 | $13,627,000,000 | $10,717,000,000 |
| Equity | ||||
| Common Stock Equity | $-3,270,000,000 | $3,325,000,000 | $10,360,000,000 | $17,254,000,000 |
| Total Equity Gross Minority Interest | $-3,228,000,000 | $3,364,000,000 | $10,397,000,000 | $17,287,000,000 |
| Stockholders Equity | $-3,270,000,000 | $3,325,000,000 | $10,360,000,000 | $17,254,000,000 |
| Gains Losses Not Affecting Retained Earnings | $-1,144,000,000 | $-1,925,000,000 | $-2,305,000,000 | $-2,199,000,000 |
| Other Equity Adjustments | $-1,144,000,000 | $-1,925,000,000 | $-2,305,000,000 | $-2,199,000,000 |
| Retained Earnings | $-15,493,000,000 | $-7,900,000,000 | $-1,000,000,000 | $4,784,000,000 |
| Other | ||||
| Treasury Shares Number | $70,802,593 | $66,337,508 | $57,105,354 | $44,589,000 |
| Ordinary Shares Number | $1,767,876,035 | $1,765,256,986 | $1,765,940,733 | $1,769,181,294 |
| Share Issued | $1,838,678,628 | $1,831,594,494 | $1,823,046,087 | $1,813,770,294 |
| Tangible Book Value | $-91,551,000,000 | $-91,699,000,000 | $-77,543,000,000 | $-82,341,000,000 |
| Invested Capital | $64,226,000,000 | $70,469,000,000 | $69,745,000,000 | $80,525,000,000 |
| Working Capital | $-14,227,000,000 | $-13,167,000,000 | $-4,839,000,000 | $-1,075,000,000 |
| Total Capitalization | $55,671,000,000 | $63,665,000,000 | $62,554,000,000 | $76,389,000,000 |
| Minority Interest | $42,000,000 | $39,000,000 | $37,000,000 | $33,000,000 |
| Treasury Stock | $9,146,000,000 | $8,201,000,000 | $6,533,000,000 | $4,594,000,000 |
| Additional Paid In Capital | $22,495,000,000 | $21,333,000,000 | $20,180,000,000 | $19,245,000,000 |
| Capital Stock | $18,000,000 | $18,000,000 | $18,000,000 | $18,000,000 |
| Common Stock | $18,000,000 | $18,000,000 | $18,000,000 | $18,000,000 |
| Employee Benefits | $1,410,000,000 | $1,234,000,000 | $1,538,000,000 | $1,638,000,000 |
| Non Current Pension And Other Postretirement Benefit Plans | $1,410,000,000 | $1,234,000,000 | $1,538,000,000 | $1,638,000,000 |
| Current Accrued Expenses | $28,043,000,000 | $26,064,000,000 | $24,179,000,000 | $19,788,000,000 |
| Investments And Advances | $268,000,000 | $279,000,000 | $304,000,000 | $241,000,000 |
| Goodwill | $35,640,000,000 | $34,956,000,000 | $32,293,000,000 | $32,156,000,000 |
| Net PPE | $5,628,000,000 | $5,134,000,000 | $4,989,000,000 | $4,935,000,000 |
| Accumulated Depreciation | $-7,902,000,000 | $-7,133,000,000 | $-6,646,000,000 | $-6,051,000,000 |
| Gross PPE | $13,530,000,000 | $12,267,000,000 | $11,635,000,000 | $10,986,000,000 |
| Construction In Progress | $1,401,000,000 | $1,093,000,000 | $1,073,000,000 | $856,000,000 |
| Other Properties | $8,785,000,000 | $7,995,000,000 | $7,449,000,000 | - |
| Buildings And Improvements | $3,057,000,000 | $2,895,000,000 | $2,827,000,000 | $2,737,000,000 |
| Land And Improvements | $287,000,000 | $284,000,000 | $286,000,000 | $286,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $1,580,000,000 | $1,173,000,000 | $1,356,000,000 | $1,162,000,000 |
| Work In Process | $2,287,000,000 | $1,951,000,000 | $1,643,000,000 | $1,417,000,000 |
| Raw Materials | $1,084,000,000 | $1,057,000,000 | $1,100,000,000 | $1,000,000,000 |
| Other Short Term Investments | $28,000,000 | $31,000,000 | $2,000,000 | $28,000,000 |
| Current Deferred Revenue | - | $14,304,000,000 | $13,627,000,000 | $10,717,000,000 |
| Machinery Furniture Equipment | - | $7,995,000,000 | $7,449,000,000 | $7,107,000,000 |
Fetched: 2026-05-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $17,816,000,000 | $17,832,000,000 | $22,062,000,000 | $24,248,000,000 |
| Operating Activities | ||||
| Operating Cash Flow | $19,030,000,000 | $18,806,000,000 | $22,839,000,000 | $24,943,000,000 |
| Cash Flow From Continuing Operating Activities | $19,030,000,000 | $18,806,000,000 | $22,839,000,000 | $24,943,000,000 |
| Operating Gains Losses | - | - | - | $-172,000,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,214,000,000 | $-974,000,000 | $-777,000,000 | $-695,000,000 |
| Investing Cash Flow | $-6,643,000,000 | $-20,820,000,000 | $-2,009,000,000 | $-623,000,000 |
| Cash Flow From Continuing Investing Activities | $-6,643,000,000 | $-20,820,000,000 | $-2,009,000,000 | $-623,000,000 |
| Net Other Investing Changes | $-29,000,000 | $189,000,000 | $13,000,000 | $774,000,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-980,000,000 | $-1,708,000,000 | $-1,972,000,000 | $-1,487,000,000 |
| Financing Cash Flow | $-12,724,000,000 | $-5,211,000,000 | $-17,222,000,000 | $-24,803,000,000 |
| Cash Flow From Continuing Financing Activities | $-12,724,000,000 | $-5,211,000,000 | $-17,222,000,000 | $-24,803,000,000 |
| Net Other Financing Charges | $45,000,000 | $-42,000,000 | $-742,000,000 | $-1,102,000,000 |
| Cash Dividends Paid | $-11,657,000,000 | $-11,025,000,000 | $-10,539,000,000 | $-10,043,000,000 |
| Common Stock Dividend Paid | $-11,657,000,000 | $-11,025,000,000 | $-10,539,000,000 | $-10,043,000,000 |
| Net Common Stock Issuance | $-980,000,000 | $-1,708,000,000 | $-1,972,000,000 | $-1,487,000,000 |
| Other | ||||
| Repayment Of Debt | $-9,595,000,000 | $-14,621,000,000 | $-4,149,000,000 | $-14,433,000,000 |
| Issuance Of Debt | $9,291,000,000 | $21,971,000,000 | $0 | $2,000,000,000 |
| Interest Paid Supplemental Data | $3,002,000,000 | $2,811,000,000 | $2,469,000,000 | $2,546,000,000 |
| Income Tax Paid Supplemental Data | $3,626,000,000 | $4,064,000,000 | $4,702,000,000 | $2,988,000,000 |
| End Cash Position | $5,229,000,000 | $5,524,000,000 | $12,814,000,000 | $9,201,000,000 |
| Beginning Cash Position | $5,524,000,000 | $12,814,000,000 | $9,201,000,000 | $9,746,000,000 |
| Effect Of Exchange Rate Changes | $42,000,000 | $-65,000,000 | $5,000,000 | $-62,000,000 |
| Changes In Cash | $-337,000,000 | $-7,225,000,000 | $3,608,000,000 | $-483,000,000 |
| Proceeds From Stock Option Exercised | $172,000,000 | $214,000,000 | $180,000,000 | $262,000,000 |
| Common Stock Payments | $-980,000,000 | $-1,708,000,000 | $-1,972,000,000 | $-1,487,000,000 |
| Net Issuance Payments Of Debt | $-304,000,000 | $7,350,000,000 | $-4,149,000,000 | $-12,433,000,000 |
| Net Short Term Debt Issuance | $2,499,000,000 | $0 | $0 | $0 |
| Short Term Debt Payments | $-2,798,000,000 | $-5,008,000,000 | $0 | $0 |
| Short Term Debt Issuance | $5,297,000,000 | $5,008,000,000 | $0 | $0 |
| Net Long Term Debt Issuance | $-2,803,000,000 | $7,350,000,000 | $-4,149,000,000 | $-12,433,000,000 |
| Long Term Debt Payments | $-6,797,000,000 | $-9,613,000,000 | $-4,149,000,000 | $-14,433,000,000 |
| Long Term Debt Issuance | $3,994,000,000 | $16,963,000,000 | $0 | $2,000,000,000 |
| Net Investment Purchase And Sale | $41,000,000 | $482,000,000 | $-22,000,000 | $92,000,000 |
| Sale Of Investment | $76,000,000 | $555,000,000 | $55,000,000 | $1,530,000,000 |
| Purchase Of Investment | $-35,000,000 | $-73,000,000 | $-77,000,000 | $-1,438,000,000 |
| Net Business Purchase And Sale | $-5,441,000,000 | $-20,517,000,000 | $-1,223,000,000 | $-794,000,000 |
| Purchase Of Business | $-5,441,000,000 | $-20,517,000,000 | $-1,223,000,000 | $-794,000,000 |
| Net PPE Purchase And Sale | $-1,214,000,000 | $-974,000,000 | $-777,000,000 | $-695,000,000 |
| Purchase Of PPE | $-1,214,000,000 | $-974,000,000 | $-777,000,000 | $-695,000,000 |
| Change In Working Capital | $-2,362,000,000 | $-2,782,000,000 | $2,813,000,000 | $-94,000,000 |
| Change In Other Working Capital | $-762,000,000 | $-3,208,000,000 | $-488,000,000 | $542,000,000 |
| Change In Payables And Accrued Expense | $951,000,000 | $177,000,000 | $3,840,000,000 | $1,769,000,000 |
| Change In Payable | $951,000,000 | $177,000,000 | $3,840,000,000 | $1,769,000,000 |
| Change In Account Payable | $951,000,000 | $177,000,000 | $3,840,000,000 | $1,769,000,000 |
| Change In Prepaid Assets | $-827,000,000 | $361,000,000 | $-188,000,000 | $-264,000,000 |
| Change In Inventory | $-234,000,000 | $-319,000,000 | $-417,000,000 | $-686,000,000 |
| Change In Receivables | $-1,490,000,000 | $207,000,000 | $66,000,000 | $-1,455,000,000 |
| Changes In Account Receivables | $-1,490,000,000 | $207,000,000 | $66,000,000 | $-1,455,000,000 |
| Other Non Cash Items | $8,643,000,000 | $4,470,000,000 | $4,811,000,000 | $3,144,000,000 |
| Stock Based Compensation | $955,000,000 | $911,000,000 | $747,000,000 | $671,000,000 |
| Provisionand Write Offof Assets | $-933,000,000 | $508,000,000 | $-443,000,000 | $2,243,000,000 |
| Asset Impairment Charge | $847,000,000 | $4,476,000,000 | $4,229,000,000 | $770,000,000 |
| Deferred Tax | $-492,000,000 | $-1,449,000,000 | $-2,889,000,000 | $-1,931,000,000 |
| Deferred Income Tax | $-492,000,000 | $-1,449,000,000 | $-2,889,000,000 | $-1,931,000,000 |
| Depreciation Amortization Depletion | $8,139,000,000 | $8,386,000,000 | $8,698,000,000 | $8,467,000,000 |
| Depreciation And Amortization | $8,139,000,000 | $8,386,000,000 | $8,698,000,000 | $8,467,000,000 |
| Amortization Cash Flow | $7,377,000,000 | $7,622,000,000 | $7,946,000,000 | $7,689,000,000 |
| Amortization Of Intangibles | $7,377,000,000 | $7,622,000,000 | $7,946,000,000 | $7,689,000,000 |
| Depreciation | $762,000,000 | $764,000,000 | $752,000,000 | $778,000,000 |
| Net Income From Continuing Operations | $4,233,000,000 | $4,286,000,000 | $4,873,000,000 | $11,845,000,000 |
| Gain Loss On Sale Of Business | - | $0 | $0 | $-172,000,000 |
Fetched: 2026-05-23